Enzon Pharmaceuticals Announces 3% Cash Dividend on Series C Preferred Stock

On December 18, 2024, Enzon Pharmaceuticals, Inc. (OTCMKTS: ENZN) filed a Form 8-K with the Securities and Exchange Commission to announce a new cash dividend. The Board of Directors has approved a 3% cash dividend aimed at the holders of the company’s 40,000 shares of Series C Non-Convertible Redeemable Preferred Stock.

The total amount of the dividend approved for distribution is $1,274,400, translating to $31.86 for each share of the Series C Preferred Stock. To be eligible for this dividend, shareholders must be recorded as holders of the Series C Preferred Stock as of January 2, 2025. The actual payment date for these dividends will be on January 9, 2025.

This decision by Enzon Pharmaceuticals is a significant financial development intended to reward its shareholders and offer them a return on their investments. It reflects the company's dedication to providing value to its investors.

In compliance with regulatory standards, Richard L. Feinstein, the Chief Executive Officer, Chief Financial Officer, and Secretary of Enzon Pharmaceuticals, signed the document on December 27, 2024, confirming the company's adherence to the disclosure obligations set forth in the Securities Exchange Act of 1934.

Enzon Pharmaceuticals, Inc. operates together with its subsidiaries; however, it does not currently engage in substantial operations. In the past, the company marketed its proprietary drug PegIntron and held a marketing agreement with Micromet AG for Vicineum, along with licensing agreements for other drugs, including SC Oncaspar.

Enzon, dividend, investors